Ekos, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Preclinical study of the firm's Lysus ultrasound-enhanced, clot-dissolving drug delivery system support potential utility in treatment of stroke. Presented the week of Nov. 8 at the American Heart Association meeting, the study compared urokinase alone to urokinase+Lysus delivery in a dog model and found that at 30 minutes, all of the vessels in the ultrasound group were open while only 50% of those in the control group were open